{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:32:01Z","timestamp":1792056721992,"version":"4.4.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cgh.2016.05.023","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T08:17:03Z","timestamp":1463991423000},"page":"1685-1696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation"],"prefix":"10.1016","volume":"14","author":[{"given":"Shomron","family":"Ben-Horin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Laszlo","family":"Lakatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2016.05.023_bib1","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. October 23, 2014. CHMP\/437\/04 Rev 1. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib2","unstructured":"U. S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. April 2015. Available at: http:\/\/www.fda.gov\/downloads\/DrugsGuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.dld.2014.07.019","article-title":"Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease","volume":"46","author":"Annese","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2016.05.023_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1155\/2013\/327120","article-title":"Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics","volume":"27","author":"Devlin","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.023_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biologicals.2014.05.005","article-title":"The challenge of indication extrapolation for infliximab biosimilars","volume":"42","author":"Feagan","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.cgh.2016.05.023_bib6","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.crohns.2014.06.007","article-title":"Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization","volume":"8","author":"Danese","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2016.05.023_bib7","unstructured":"World Health Organization. Expert Committee on Biological Standardization: guidelines on evaluation of similar biotherapeutic products. 2009. Available at: http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed February 28,\u00a02016."},{"issue":"Suppl 5","key":"10.1016\/j.cgh.2016.05.023_bib8","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.semarthrit.2016.01.002","article-title":"Development of biosimilars","volume":"45","author":"Al-Sabbagh","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.cgh.2016.05.023_bib9","unstructured":"U. S. Food and Drug Administration. Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Available at: http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm122879.htm. Accessed April 4,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib10","unstructured":"International Conference on Harmonisation. Q5E Comparability of biotechnological\/biological products subject to changes in their manufacturing process. Available at: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q5E\/Step4\/Q5E_Guideline.pdf. Accessed April 4,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib11","unstructured":"INFLECTRA prescribing information. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125544s000lbl.pdf. Accessed April 11,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A\u00a0randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2016.05.023_bib13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2016.05.023_bib14","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A\u00a0randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2016.05.023_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","article-title":"A\u00a0phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2016.05.023_bib16","doi-asserted-by":"crossref","unstructured":"Park W, Yoo DH, Miranda P, et\u00a0al. Efficacy and safety of switching from reference infliximab to CT-P13 compared to maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 2016; http:\/\/dx.doi.org\/10.1136\/annrheumdis-2015-208783.","DOI":"10.1136\/annrheumdis-2015-208783"},{"key":"10.1016\/j.cgh.2016.05.023_bib17","doi-asserted-by":"crossref","unstructured":"Yoo DH, Prodanovic N, Jaworski, J, et\u00a0al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2016; http:\/\/dx.doi.org\/10.1136\/annrheumdis-2015-208786.","DOI":"10.1136\/annrheumdis-2015-208786"},{"key":"10.1016\/j.cgh.2016.05.023_bib18","unstructured":"Health Canada. Regulatory decision summary for REMSIMA (Control number 184568). August 5,\u00a02016. Available at: http:\/\/www.hc-sc.gc.ca\/dhp-mps\/prodpharma\/rds-sdr\/drug-med\/rds-sdr-remsima-184568-eng.php. Accessed October\u00a07,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-eular.1583","article-title":"A\u00a0randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy","author":"Choe","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2016.05.023_bib20","article-title":"BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses: 54-week results of a randomized, double-blind, active comparator study","volume":"66","author":"Kay","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib21","unstructured":"Nichi-Iko Pharmaceuticals. Phase III testing for NI-071 results (preliminary report). June 22, 2015. Available at: http:\/\/www.nichiiko.co.jp\/finance\/gif\/4541_20150622_01.pdf. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib22","unstructured":"Biogen press release. FLIXABI\u00ae, Biogen's infliximab biosimilar referencing Remicade\u00ae, approved in the European Union. May 30, 2016. Available at: http:\/\/media.biogen.com\/press-release\/biosimilars\/flixabi-biogens-infliximab-biosimilar-referencing-remicade-approved-europe. Accessed October 7, 2016."},{"key":"10.1016\/j.cgh.2016.05.023_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.2166","article-title":"A\u00a0randomized, single-blind, single-dose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP-501 and adalimumab: results of comparison with adalimumab (EU)","volume":"73","author":"Kaur","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2016.05.023_bib24","unstructured":"Amgen press release. Amgen announces positive top-line results from phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with adalimumab in patients with moderate-to-severe plaque psoriasis. October 8,\u00a02014. Available at: http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=1975377. Accessed February 28,\u00a02016."},{"issue":"Suppl 10","key":"10.1016\/j.cgh.2016.05.023_bib25","first-page":"A2054","article-title":"Randomized, double-blind, phase 3 study of efficacy and safety of ABP 501 compared with adalimumab in subjects with moderate to severe rheumatoid arthritis","volume":"67","author":"Cohen","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2016.05.023_bib26","unstructured":"European Medicines Agency. Remsima assessment report. June 27, 2013. EMA\/CHMP\/589317\/2013. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002576\/WC500151486.pdf. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03946320140270S101","article-title":"The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases","volume":"27","author":"Blandizzi","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.cgh.2016.05.023_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cytogfr.2014.07.016","article-title":"TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants\u2014past, present and future","volume":"25","author":"Sedger","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.cgh.2016.05.023_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.2006.105379","article-title":"Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease","volume":"56","author":"Van den Brande","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.023_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2036.2005.02309.x","article-title":"Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept","volume":"21","author":"Shen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.05.023_bib31","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes\u00a0from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.023_bib32","unstructured":"European Medicines Agency. Benepali assessment report. November 19, 2015. EMA\/CHMP\/819219\/2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/004007\/WC500200380.pdf. Accessed April 4,\u00a02016."},{"issue":"Suppl","key":"10.1016\/j.cgh.2016.05.023_bib33","article-title":"Demonstration of functional similarity comparing adalimumab to biosimilar candidate ABP 501","volume":"10","author":"Born","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2016.05.023_bib34","unstructured":"U. S. Food and Drug Administration. FDA briefing document. Arthritis Advisory Committee Meeting. BLA 125544. February 9, 2016. Available at: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ArthritisAdvisoryCommittee\/UCM484859.pdf. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2010.10.008","article-title":"Anti\u2013tumor necrosis factor-\u03b1 antibodies induce regulatory macrophages in an Fc region-dependent manner","volume":"140","author":"Vos","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.023_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ibd.21818","article-title":"Regulatory macrophages induced by infliximab are involved in healing in\u00a0vivo and in\u00a0vitro","volume":"18","author":"Vos","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2016.05.023_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/gutjnl-2012-302262","article-title":"Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol","volume":"62","author":"Hebuterne","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.023_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ecco-jcc\/jjv179","article-title":"Fc receptor-mediated effector function contributes to the therapeutic response of anti-TNF monoclonal antibodies in a mouse model\u00a0of inflammatory bowel disease","volume":"10","author":"McRae","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2016.05.023_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling NK cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.cgh.2016.05.023_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2036.2004.01871.x","article-title":"Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease","volume":"19","author":"Louis","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2016.05.023_bib41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00251-013-0679-8","article-title":"FCGR3A-158 polymorphism influences the biological response to infliximab in Crohn's disease through affecting the ADCC activity","volume":"65","author":"Moroi","year":"2013","journal-title":"Immunogenetics"},{"key":"10.1016\/j.cgh.2016.05.023_bib42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/01.fpc.0000230421.12844.fd","article-title":"Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study","volume":"16","author":"Louis","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.cgh.2016.05.023_bib43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40262-014-0225-3","article-title":"Assessment of the influence of inflammation and FCGR3A genotype on infliximab pharmacokinetics and time to relapse in patients with Crohn's disease","volume":"54","author":"Ternant","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2016.05.023_bib44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/ajg.2008.138","article-title":"Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease","volume":"104","author":"Baumgart","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.023_bib45","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.cgh.2016.05.023_bib46","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.05.023_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/17474124.2015.1091306","article-title":"The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13","volume":"9","author":"Reinisch","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","article-title":"Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis","volume":"25","author":"Takeuchi","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.05.023_bib49","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1586\/1744666X.2015.1090311","volume":"11","author":"Park","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.cgh.2016.05.023_bib50","article-title":"Pharmacokinetic results from a phase 1, single-centre, double-blind, randomised, single-dose, parallel group study comparing 5 mg\/kg IV infusion of BOW015 and reference infliximab in healthy male volunteers","volume":"74","author":"Lambert","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"10.1016\/j.cgh.2016.05.023_bib51","first-page":"A2727","article-title":"BI 695501, a proposed biosimilar for adalimumab, shows bioequivalence to adalimumab reference products in a randomized, double-blind phase I trial in healthy subjects","volume":"67","author":"Wynne","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib52","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2016.05.023_bib53","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cgh.2016.05.023_bib54","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270008316886","article-title":"Population pharmacokinetics of infliximab in patients with ankylosing spondylitis","volume":"48","author":"Xu","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2016.05.023_bib55","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"10.1016\/j.cgh.2016.05.023_bib56","first-page":"S39","article-title":"Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice","volume":"55","author":"Vande Casteele","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.cgh.2016.05.023_bib57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study","volume":"65","author":"Yarur","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.023_bib58","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1208\/s12248-013-9534-y","article-title":"Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?","volume":"16","author":"Lee","year":"2014","journal-title":"AAPS J"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.05.023_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/17474124.2015.1091307","article-title":"The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?","volume":"9","author":"Ben-Horin","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib60","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1053\/j.gastro.2013.11.024","article-title":"Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease","volume":"146","author":"Feagan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2016.05.023_bib61","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2016.05.023_bib62","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima","volume":"65","author":"Ben-Horin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2016.05.023_bib63","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2016.05.023_bib64","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s10350-006-0656-5","article-title":"Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment","volume":"49","author":"Hyder","year":"2006","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.cgh.2016.05.023_bib65","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/ajg.2011.211","article-title":"The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety","volume":"106","author":"Van Assche","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.023_bib66","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1572-0241.2006.00463.x","article-title":"Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease","volume":"101","author":"Lichtenstein","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.023_bib67","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3748\/wjg.14.1885","article-title":"Effect of infliximab on small bowel stenoses in patients with Crohn\u2019s disease","volume":"14","author":"Pallotta","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2016.05.023_bib68","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","article-title":"Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis: experiences from a single center","volume":"15","author":"Farkas","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cgh.2016.05.023_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort","volume":"10","author":"Gecse","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.05.023_bib70","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","article-title":"Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study","volume":"9","author":"Jahnsen","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib71","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/jgh.12997","article-title":"Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study","volume":"30","author":"Jung","year":"2015","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib72","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10620-014-3392-z","article-title":"Clinical experience of the use\u00a0of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series","volume":"60","author":"Kang","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2016.05.023_bib73","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3109\/00365521.2016.1149883","article-title":"Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"51","author":"Keil","year":"2016","journal-title":"Scand J Gastroenterol"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.05.023_bib74","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","article-title":"Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea","volume":"9","author":"Park","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2016.05.023_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease: preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2016.05.023_bib76","article-title":"Biosimilar but not the same","volume":"9","author":"Murphy","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2016.05.023_bib77","unstructured":"U. S. Food and Drug Administration. Information on biosimilars. Available at: http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/default.htm. Accessed March 25,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib78","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s10620-015-3673-1","article-title":"Preemptive dose optimization using therapeutic drug monitoring for biologic therapy of Crohn's disease: avoiding failure while lowering costs?","volume":"60","author":"Vande Casteele","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2016.05.023_bib79","unstructured":"ClinicalTrials.gov. Demonstrate noninferiority in efficacy and to assess safety of CT-P13 in patients with active Crohn's disease. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02096861. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib80","unstructured":"ClinicalTrials.gov. The NOR-SWITCH Study. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02148640. Accessed February 28,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib81","unstructured":"Generics and Biosimilars Initiative. Merck Group starts phase III trial for adalimumab biosimilar. March 18, 2016. Available at: http:\/\/www.gabionline.net\/Biosimilars\/News\/Merck-Group-starts-phase-III-trial-for-adalimumab-biosimilar. Accessed April 5,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib82","unstructured":"ClinicalTrials.gov. A study to compare FKB327 efficacy and safety with Humira\u00ae in rheumatoid arthritis patients (ARABESC). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02260791. Accessed April 5,\u00a02016."},{"key":"10.1016\/j.cgh.2016.05.023_bib83","unstructured":"ClinicalTrials.gov. Pharmacokinetics and safety study of LBAL in healthy subjects. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02206867. Accessed April 5,\u00a02016."}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516302129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356516302129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:20:36Z","timestamp":1761542436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356516302129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":83,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1542356516302129"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2016.05.023","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2016.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the AGA Institute","name":"copyright","label":"Copyright"}]}}